Author

J. Wang

Observed names: Jiaxin Wang, Jinbei Wang

Institutions: Shanghai Medical College of Fudan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University Shanghai Cancer Center, Hunan Provincial People's Hospital

Observed institutions: Shanghai Medical College of Fudan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University Shanghai Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences, Hunan Provincial People's Hospital, Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences

ORCID: 0000-0001-7351-4190

Observed ORCID: 0000-0001-7351-4190

OpenAlex ID: A5031729031

HLA common and well‐documented alleles in China

2018 · Y. He, J. Li, et al. · HLA · 122

Exogenous bFGF promotes articular cartilage repair via up-regulation of multiple growth factors

2013 · X. Li, G. Su, et al. · Osteoarthritis and Cartilage · 40

PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

2025 · D. Planchard, P.A. Jänne, et al. · Journal of Thoracic Oncology · 11

P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer

2019 · Y. Wu, C. Huang, et al. · Journal of Thoracic Oncology · 8

TWAS atlas 2.0: an updated data resource for transcriptome-wide association studies

2025 · Hao Gao, Congfan Bu, et al. · Nucleic Acids Research · 4

Identification of a novel HLA‐C*03 variant, C*03:303, by sequence‐based typing in a Dai Chinese individual

2016 · P. C. Su, J. Wang, et al. · HLA · 4

Identification of a novel HLA‐C allele, HLA‐C*07:477 in a Drung Chinese individual

2016 · J. Wang, F. Z. Yao, et al. · HLA · 4

84P Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase III CAPSTONE-1 study

2023 · Y. Cheng, J. Wang, et al. · Immuno-Oncology Technology · 3

2690MO Extended efficacy and safety from the phase III MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour (TGCT)

2025 · H. Gelderblom, V. Ravi, et al. · Annals of Oncology · 2

The GWAS SNP rs80207740 modulates erythrocyte traits via allele‐specific binding of IKZF1 and targeting XPO7 gene

2024 · Xinjun Hu, Jiaxin Wang, et al. · The FASEB Journal · 1

MA 06.09 Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC

2017 · X. Zhang, Z. Liang, et al. · Journal of Thoracic Oncology · 1

74P Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study

2024 · J-J. Yang, C. Huang, et al. · ESMO Open

P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC

2021 · C. Huang, Y. Wu, et al. · Journal of Thoracic Oncology

Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

2018 · Q. Zhou, H. Zhang, et al. · Annals of Oncology

Diversity of killer cell immunoglobulin‐like receptor genes in Drung Chinese

2016 · L. Jiang, P. Su, et al. · HLA

Works count: 15

Citation count: 199

H-index: 4

I10-index: 3